.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Breast Cancer

Payer Perspective of Coverage on Cancer Therapies

The role of PI3 kinase inhibition in various settings in metastatic breast cancer and a payer perspective on differentiating breast cancer at various stages of disease progression.

Payer Coverage on Repeat Biopsy in MBC

Testing patients who have received CDK4/6 inhibitors in metastatic breast cancer (MBC) as well as testing patients with ctDNA upon disease progression with a single gene test versus NGS.

Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography

April 20th 2022, 10:13pm

Article

This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.

Dr Debra Patt Discusses Considering Strategies for Additional COVID-19 Boosters in Breast Cancer

April 16th 2022, 12:54pm

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL

April 13th 2022, 3:01pm

Article

This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.

Mixed QOL Findings Following Treatment Highlight Need for BC Support Services

April 9th 2022, 4:46pm

Article

This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.

Dr Debra Patt: Do Not Delay Diagnostic Visits for Breast Cancer

April 4th 2022, 10:42am

Video

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, explains recommendations for annual mammography screenings after COVID-19 vaccination and why guidelines differ for diagnostic visits.

CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates

April 1st 2022, 4:02pm

Article

NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

AI Shows Promise in Detecting Breast Cancer in Women

March 29th 2022, 2:01pm

Article

In this new study from Norway, artificial intelligence (AI) was used with mammography screenings to predict risk of breast cancer in women vs double reading of mammographic screening by independent radiologists.

MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine

March 23rd 2022, 9:01pm

Article

This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.

Breast Arterial Calcification May Increase Risk of ASCVD

March 21st 2022, 6:07pm

Article

The presence of breast arterial calcification may serve as a biomarker for an increased risk of cardiovascular disease among postmenopausal women.

Considerations to Increase Rates of Breast Cancer Screening Across Populations

March 14th 2022, 7:00pm

Article

Authors from the Community Oncology Alliance and Avalere Health present data that show breast cancer screening rates recovered more slowly among some racial/ethnic groups following on the onset of the COVID-19 pandemic.